International 22q11.2 Brain Behavior Consortium

Ruth and Tristram Colket, Jr. Translational Research Building
3501 Civic Center Blvd, Philadelphia, PA 19104  Map

Jun 29, 2015-Jun 30, 2015

Course Overview

Following on the heels of previous successful meetings in Leuven, Belgium; Dublin, Ireland; and Mallorca, Spain, the IBBC is now operational as a large-scale initiative studying the genetics of schizophrenia and other psychiatric disorders associated with chromosome 22q11.2 deletions (22q11.2DS). With $12 million in support from the National Institute of Mental Health of the National Institutes of Health in the United States, this multicenter endeavor is examining findings associated with 22q11.2DS across the life span while utilizing whole genome sequencing in search of phenotype-genotype correlations with the ultimate goals of improving detection, treatment and long-term outcomes. Beyond the potential for yielding a better understanding of a severe manifestation of 22q11.2DS, the results will help identify pathways leading to schizophrenia in the general population in a way that will inform novel treatments, as there is a substantial risk for developing psychotic illness in approximately 25 to 30 percent of adolescents and young adults with 22q11.2DS. The illness presentation and course are similar to those of schizophrenia, which occurs in the general population at a much lower rate (about 1 percent). All members of the Consortium are invited to attend.